Co-treatment with the novel, oral, multi-targeted kinase inhibitor, dasatinib (BMS-354825) and the histone deacetylase inhibitor corinostat (suberoylanilide hydroxamic acid, SAHA): A highly active combination against wild-type or mutant Bcr-Abl-T315I containing human leukemia cells.

被引：0
|
作者：
Fiskus, W
Pranpat, M
Bali, P
Balasis, M
Kumaraswamy, S
Boyapalle, S
Rocha, K
Lee, F
Richon, V
Bhalla, K
机构：
[1] H Lee Moffit Canc Ctr & Res Inst, Tampa, FL USA
[2] Bristol Myers Squibb Co, Princeton, NJ USA
[3] Merck & Co Inc, Boston, MA USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9028S / 9028S
页数：1
相关论文
共 3 条
  • [1] Co-treatment with a novel heat shock protein (hsp) 90 inhibitor IPI504 and the histone deacetylase inhibitor (HDI) vorinostat (suberoylanilide hydroxamic acid, SAHA): A highly active combination against wild type or mutant Bcr-Abl-T315I or FLT-3-ITD-containing human leukemia cells.
    Fiskus, W
    Bali, P
    Pranpat, M
    Balasis, M
    Kumaraswamy, S
    Boyapalle, S
    Rocha, K
    Tong, J
    Richon, V
    Normant, E
    Bhalla, K
    BLOOD, 2005, 106 (11) : 193B - 194B
  • [2] Co-treatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances the cytotoxic effects of gleevee and arsenic trioxide (AT) against Ber-Abl positive human leukemia cells
    Bhalla, KN
    Nimmanapalli, R
    Stobaugh, C
    Fuino, L
    Richon, V
    BLOOD, 2002, 100 (11) : 270B - 270B
  • [3] Co-treatment with the hsp90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and histone deacetylase inhibitor (HDI) vorinostat (suberoylanilide hydroxamic acid, SAHA): A highly active combination against human mantle cell lymphoma (MCL) cells.
    Hatter, A
    Bali, P
    Balasis, M
    Fiskus, W
    Boyapalle, S
    Kumaraswamy, S
    Rocha, K
    Pranpat, M
    Hannah, A
    Sotomayor, E
    Richon, V
    Bhalla, K
    BLOOD, 2005, 106 (11) : 680A - 680A
1